A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 459 participants.

Also called NCT02547935

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 459 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02547935
Other papers using this trial's data
  • Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial The lancet. Diabetes & endocrinology, 2019-06 DOI, PubMed 30992195
  • Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial Cardiovascular diabetology, 2023-11-28 DOI, PubMed 38017482, PMC10685512 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Japan, Mexico, South Africa, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02547935. Randomized; double masking; primary purpose treatment. Start 2015-09-21 (actual); primary completion 2018-05-18 (actual). Results posted on 2019-06-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
Condition
Type 2 Diabetes Mellitus, CKD (chronic kidney disease) and Albuminuria
Intervention (Drug)
Dapagliflozin 10 mg
Intervention (Drug)
Saxagliptin 2.5 mg
Intervention (Drug)
Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02547935
Content hash
27e10bc65f5c445d9a456d78581d7ef7ca4e69204a3c7fc83c9d7e6b48b545c7